Industry
Biotechnology
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 4:23 pm
Portfolio Pulse from Benzinga Newsdesk
August 07, 2024 | 8:19 pm
Portfolio Pulse from Benzinga Newsdesk
August 07, 2024 | 5:59 pm
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 8:39 pm
Portfolio Pulse from Benzinga Insights
June 04, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Newsdesk
June 04, 2024 | 11:02 am
Portfolio Pulse from Avi Kapoor
June 03, 2024 | 5:56 pm
Portfolio Pulse from Benzinga Insights
June 03, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Newsdesk
May 15, 2024 | 5:58 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.